




PTO/SB/08A				<div style="text-align: center;">  </div>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/805,337
				Filing Date	March 13, 2001
				Confirmation Number	1925
				First Named Inventor	Brendan F. Murphy
Sheet	1	of	4	Attorney Docket No.	DI-5585L (BXTD 9000.1)

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	1	4,554,101	—	Hopp	11-19-1985
	2	4,703,004	—	Hopp et al.	10-27-1987
	3	4,782,137	—	Hopp et al.	11-01-1988
	4	4,848,341	—	Ahmad	07-18-1989
	5	5,594,115	—	Sharma	01-14-1997
	6	5,861,155	—	Lin	01-19-1999
	7	5,935,824	—	Sgarlato	08-10-1999

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	8	ALSENZ et al., Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H, <i>Biochem. J.</i> , Dec. 1984, pp. 389-98, Vol. 224, No. 2, Biochemical Society, London, Great Britain	
	9	ALSENZ et al., Structural and functional analysis of the complement component Factor H with the use of different enzymes and monoclonal antibodies to Factor H, <i>Biochem J.</i> , Dec. 1985, pp. 841-50, Vol. 232, No. 3, Biochemical Society, London, Great Britain	
	10	ALTSCHUL et al., Basic Local Alignment Search Tool, <i>J. Mole. Biol.</i> , Oct. 1990, pp. 403-10, Vol. 215, No. 3, Academic Press	
	11	BIRREN et al., Title of Article Unknown, <i>Genome Analysis</i> , 1997, Vol. 1, pp. 543-559	

Examiner Signature		Date Considered	8/13/03
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/805,337
				Filing Date	March 13, 2001
				Confirmation Number	1925
				First Named Inventor	Brendan F. Murphy
Sheet	2	of	4	Attorney Docket No.	DI-5585L (BXTD 9000.1)


②	12	BRÜGGEMANN et al., Production of human antibody repertoires in transgenic mice, <i>Current Opinion Biotech.</i> , Aug. 1997, pp. 455-58, Vol. 8, No. 4, Current Biology Ltd., London, Great Britain	
	13	BURNETTE, "Western Blotting": Electrophoretic Transfer of Proteins from Sodium Dodecyl Sulfate-Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody and Radioiodinated Protein A, <i>Anal. Biochem.</i> , Apr. 1981, pp. 195-203, Vol. 112, No. 2, Academic Press	
	14	CARRILLO et al., The Multiple Sequence Alignment Problem In Biology, <i>Applied Math.</i> , Oct. 1988, pp. 1073-82, Vol. 48, No. 5, Society for Industrial and Applied Mathematics, Philadelphia, PA, USA	
	15	CLACKSON et al., Making antibody fragments using phage display libraries, <i>Nature</i> , Aug. 1991, pp. 624-28, Vol. 352, No. 6336, Macmillan Magazines Ltd., London, Great Britain	
	16	COULSON, High-performance searching of biosequence databases, <i>Trends in Biotech.</i> , Mar. 1994, pp. 76-80, Vol. 12, No. 3, Elsevier Science Ltd.	
④	17	DEVEREAU et al., Comprehensive set of sequence analysis programs for the VAX, <i>Nucleic Acids Res.</i> , Jan. 1984, pp. 387-95, Vol. 12, No. 1, IRL Press, Oxford, England	
⑫	18	FRENKEN et al., Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms, <i>Res. Immunol.</i> , Jul. 1998, pp. 589-99, Vol. 149	
	19	FUNAKOSHI et al., Proline-rich protein is a glycoprotein and an acute phase reactant, <i>Biochim. Biophys. Acta</i> , 1988, pp. 98-108, Vol. 963, Elsevier Science Publishers B.V.	
	20	GORDON et al., Identification of Complement Regulatory Domains in Human Factor H <sup>1</sup> , <i>J. Immunol.</i> , Jul. 1995, pp. 348-56, Vol. 155, No. 1, Amer. Assoc. of Immunologists, USA	
	21	GRIFFITHS et al., Isolation of high affinity human antibodies directly from large synthetic repertoires, <i>EMBO J.</i> , Jul. 1994, pp. 3245-60, Vol. 13, No. 14	
②	22	HOURCADE et al., The Regulators of Complement Activation (RCA) Gene Cluster, <i>Adv. Immunol.</i> , 1989, pp. 381-416, Vol. 45, Academic Press	
⑫	23	HUSE et al., Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda, <i>Science</i> , Dec. 1989, pp. 1275-81, Vol. 246, Amer. Assoc. for the Advancement of Science, Washington, D.C., USA	
⑫	24	JENNE et al., Clusterin (Complement Lysis Inhibitor) Forms a High Density Lipoprotein Complex with Apolipoprotein A-I in Human Plasma, <i>J. Biol. Chem.</i> , Jun. 1991, pp. 11030-36, Vol. 266, No. 17, Amer. Society for Biochemistry and Molecular Biology, USA	

Examiner Signature		Date Considered	8/13/03
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



<b>PTO/SB/08A</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/805,337
				Filing Date	March 13, 2001
				Confirmation Number	1925
				First Named Inventor	Brendan F. Murphy
Sheet	3	of	4	Attorney Docket No.	DI-5585L (BXTD 9000.1)

25	25	JENNE et al., Clusterin: the intriguing guises of a widely expressed glycoprotein, <i>Trends in Biochem. Sci.</i> , 1992, pp. 154-59, Vol. 17, Elsevier Science Publishers	
26	26	JONES et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse, <i>Nature</i> , 1986, pp. 522-25, Vol. 321, No. 6069, Macmillan Journals Ltd., London, Great Britain	
27	27	KOHLER et al., Continuous cultures of fused cells secreting antibody of predefined specificity, <i>Nature</i> , Aug. 1975, pp. 495-97, Vol. 256, No. 5517, Macmillan Journals Ltd., London, Great Britain	
28	28	KOZBOR et al., The production of monoclonal antibodies from human lymphocytes, <i>Immun. Today</i> , 1983, pp. 72-79, Vol. 4, No. 3, Elsevier Science Publishers	
29	29	KÜHN et al., Mapping of the Complement Regulatory Domains in the Human Factor H-Like Protein 1 and in Factor H <sup>1</sup> , <i>J. Immunol.</i> , Dec. 1995, pp. 5663-70, Vol. 155, No. 12, Amer. Assoc. of Immunologists, USA	
30	30	KÜHN et al., Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H, <i>Eur. J. Immunol.</i> , 1996, pp. 2383-87, Vol. 26, VCH Publishers, New York, NY, USA	
31	31	MARKS et al., By-passing Immunization - Human Antibodies from V-gene Libraries Displayed on Phage, <i>J. Molec. Biol.</i> , Dec. 1991, pp. 581-97, Vol. 222, No. 3, Academic Press	
32	32	MERI, Complement Lysis Inhibitor and Prototype Domain in a New Protein Superfamily, <i>The Immunol.</i> , 1994, pp. 149-55, Vol. 2	
33	33	MITCHELHILL et al., Posttranslational Modifications of the 5'-AMP-activated Protein Kinase $\beta_1$ Subunit, <i>J. Biolog. Chem.</i> , Sep. 1997, pp. 24475-79, Vol. 272, No. 39, Amer. Soc. for Biochemistry and Molecular Biology, USA	
34	34	MURPHY et al., Identification Of The Components Of Glomerular Immune Deposits Using Monoclonal Antibodies, <i>Pathology</i> , 1988, pp. 130-36, Vol. 20, Modern Medicine	
35	35	Oi et al., Immunoglobulin-Producing Hybrid Cell Lines, <i>Selected Meth. Cell. Immunol.</i> , 1980, pp. 351-72, W.H. Freeman and Company, San Francisco, CA, USA	
36	36	PARK et al., Plasma Lipopolysaccharide-binding Protein Is Found Associated with a Particle Containing Apolipoprotein A-I, Phospholipid, and Factor H-related Proteins, <i>J. Biol. Chem.</i> , Jul. 1996, pp. 18054-60, Vol. 271, No. 30, Amer. Soc. for Biochemistry and Molecular Biology, USA	

Examiner Signature		Date Considered	8/13/03
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



<b>PTO/SB/08A</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/805,337
				Filing Date	March 13, 2001
				Confirmation Number	1925
				First Named Inventor	Brendan F. Murphy
Sheet	4	of	4	Attorney Docket No.	DI-5585L (BXTD 9000.1)

<input checked="" type="checkbox"/>	37	RIPOCHE et al., The complete amino acid sequence of human complement factor H, <i>Biochem. J.</i> , Jan. 1988, pp. 593-602, Vol. 249, No. 2, Biochemical Society, London, Great Britain	
	38	SCHWAEBLE et al., Human complement factor H: expression of an additional truncated gene product of 43 kDa in human liver, <i>Eur. J. Immunol.</i> , Jul. 1987, pp. 1485-89, Vol. 17	
	39	SHARMA et al., Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis, <i>Proc. Natl. Acad. Sci.</i> , Oct. 1996, pp. 10996-11001, Vol. 93, No. 20, Natl. Acad. of Sciences, USA	
	40	SKERKA et al., The Human Factor H-related Protein 4 (FHR-4), <i>J. Biol. Chem.</i> , Feb. 1997, pp. 5627-34, Vol. 272, No. 9, Amer. Soc. for Biochemistry and Molecular Biology, USA	
	41	SOAMES et al., An investigation of the interaction between human complement factor H and C3b, <i>Biochem. Soc. Trans.</i> , Feb. 1995, p. 53S, Vol. 23, No. 1	
	42	VÄKEVÄ et al., High-density lipoproteins can act as carriers of glycoposphoinositol lipid-anchored CD59 in human plasma, <i>Immunol.</i> , May 1994, pp. 28-33, Vol. 82, No. 1, Blackwell Scientific Publications	
	43	VAUGHAN et al., Human antibodies by design, <i>Nature Biotech.</i> , Jun. 1998, pp. 535-39, Vol. 16, No. 6	
	44	WATERHOUSE et al., Combinatorial infection and <i>in vivo</i> recombination: a strategy for making large phage antibody repertoires, <i>Nuc. Acids Res.</i> , May 1993, pp. 2265-66, Vol. 21, No. 9, IRL Press, Oxford, England	
	45	WATKINS et al., Introduction to Antibody Engineering and Phage Display, <i>Vox Sanguinis</i> , Mar. 2000, pp. 72-79, Vol. 78, S. Karger AG, Basel	
	46	WÜRZNER et al., Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neopeptide-specific monoclonal antibodies, <i>Immunol.</i> , Sep. 1991, pp. 132-38, Vol. 74, No. 1, Blackwell Scientific Publications	
<input checked="" type="checkbox"/>	47	ZIPFEL et al., Complement factor H and related proteins: an expanding family of complement-regulatory proteins?, <i>Immunol. Today</i> , Nov. 1994, pp. 121-26, Vol. 15, No. 11, Elsevier Science Ltd.	

Examiner Signature		Date Considered	8/13/03
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



AUG 0 9 2001

PTO/SB/D8A AUG 0 3 2001 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/805,337
				Filing Date	March 13, 2001
				Confirmation Number	1925
				First Named Inventor	Brendan F. Murphy
Sheet	1	of	1	Attorney Docket No.	DI-5585L (BXTD 9000.1)

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*			
	11	BIRREN et al., <i>Genome Analysis</i> , 1997, Vol. 1, pp. 543-559	

Examiner Signature		Date Considered	8/13/03
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.